Clinical Trials Logo
  1. Home
  2. Eczema
  3. NCT05935085

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).

Atopic Dermatitis Eczema Clinical Trial

Official title:
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis

Clinical Trial Summary

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Clinical Trial Description

This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05935085
Study type Interventional
Source AnaptysBio, Inc.
Contact Aaron Ilan
Phone 858-732-0100
Email Clinicaltrialinfo@anaptysbio.com
Status Recruiting
Phase Phase 2
Start date June 13, 2023
Completion date January 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT05579899 - Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis Phase 2
Terminated NCT04085549 - Effects of a Berry Oil Cream on Atopic Eczema and Skin N/A
Recruiting NCT05578482 - Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis Phase 4
Completed NCT03540043 - Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis Phase 2
Recruiting NCT03293030 - Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Phase 4
Completed NCT03386032 - 8-Week Atopic Dermatitis (AD) Treatment Study Phase 3
Completed NCT03667014 - The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients Phase 4
Terminated NCT05382819 - A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis Phase 1
Completed NCT04537468 - Development of a Method to Measure mRNA Levels in Skin Samples N/A
Completed NCT03268174 - Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis. N/A
Active, not recruiting NCT03859986 - Study in Subjects With Moderate Atopic Dermatitis Phase 2
Completed NCT04800185 - Characterizing Skin Microbiome Change in Atopic Dermatitis Early Phase 1
Completed NCT06361992 - Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children Phase 3
Recruiting NCT06024499 - Phase 2 Trial of HY209gel in Atopic Dermatitis Patients Phase 2
Recruiting NCT03742414 - Seal, Stopping Eczema and Allergy Study Phase 3
Completed NCT03090178 - Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy N/A
Recruiting NCT03795506 - TLA in Children With Moderate to Severe Atopic Eczema (TLA4AE) N/A
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Completed NCT04773587 - Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis Phase 3
Active, not recruiting NCT04017520 - Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time